Your browser doesn't support javascript.
loading
An observational study investigating failure of primary endocrine therapy for operable breast cancer in the elderly.
Thomas, Robert; Rowell, Rachel; Crichton, Siobhan; Cain, Henry.
Afiliación
  • Thomas R; Queen Elizabeth Hospital, Gateshead, NE9 6SX, UK. roberthuwthomas@doctors.org.uk.
  • Rowell R; , 48 Larkspur Terrace, Jesmond, Newcastle upon Tyne, NE2 2DU, UK. roberthuwthomas@doctors.org.uk.
  • Crichton S; Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK.
  • Cain H; Medical Research Council Clinical Trials Unit, University College London, Aviation House, 125 Kingsway, London, WC2B 6NH, UK.
Breast Cancer Res Treat ; 167(1): 73-80, 2018 01.
Article en En | MEDLINE | ID: mdl-28879429
ABSTRACT

BACKGROUND:

Elderly patients are more likely to have oestrogen receptor positive cancers that can be treated without surgery with primary endocrine therapy (PET). Few studies have sought to identify predictors of failure of PET and so the aim of this study was to evaluate treatment failures in elderly breast cancer patients treated with PET and to determine predictors of failure.

METHODS:

A retrospective observational study was performed on consecutive patients with ER-positive early stage breast cancer treated with PET between 2005 and 2015 in the three breast units in the North East of England. The primary outcome measure was treatment failure and secondary outcome measure was disease progression.

RESULTS:

488 patients were included with mean follow-up 31 months (SD 23). Overall, 206 patients were still alive with their disease controlled at the end of follow-up, 219 had died with their disease controlled and 63 (12%) experienced treatment failure. Younger age [SHR 0.96 (95% CI 0.94-0.99) p 0.013], larger tumours [SHR 1.03 (1.01-1.06) p 0.015], grade 3 cancers [SHR 3.58 (1.93-6.63) p < 0.001] and axillary lymph node metastases [SHR 1.93 (1.06-3.52) p 0.030] were all independent predictors of treatment failure. Disease progression was reported in 86 (17.6%) of patients.

CONCLUSIONS:

This is the largest retrospective series evaluating PET treatment failure. Clear predictors of failure have been identified, which can be used to facilitate treatment decision making. These results support previous analyses, further validating our results.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tamoxifeno / Neoplasias de la Mama / Antineoplásicos Hormonales Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans País/Región como asunto: Europa Idioma: En Revista: Breast Cancer Res Treat Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tamoxifeno / Neoplasias de la Mama / Antineoplásicos Hormonales Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans País/Región como asunto: Europa Idioma: En Revista: Breast Cancer Res Treat Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido